News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
41,907 Results
Type
Article (1867)
Company Profile (8)
Press Release (40032)
Section
Business (17233)
Career Advice (19)
Deals (2809)
Drug Development (5163)
FDA (660)
Job Trends (810)
News (24724)
Policy (1309)
Tag
Academia (77)
Accelerated approval (4)
Allergies (6)
Alliances (1559)
ALS (8)
Alzheimer's disease (56)
Antibody-drug conjugate (ADC) (29)
Approvals (701)
Artificial intelligence (14)
Autoimmune disease (5)
Automation (1)
Bankruptcy (16)
Best Places to Work (776)
Biosimilars (3)
Biotechnology (4)
Bladder cancer (19)
Brain cancer (3)
Breast cancer (70)
Cancer (393)
Cardiovascular disease (26)
Career advice (17)
CAR-T (19)
Cell therapy (40)
Cervical cancer (2)
Clinical research (4744)
Collaboration (80)
Company closure (1)
Compensation (110)
Complete response letters (2)
COVID-19 (81)
C-suite (22)
Cystic fibrosis (9)
Data (611)
Depression (14)
Diabetes (41)
Diagnostics (327)
Digital health (2)
Diversity (1)
Drug discovery (11)
Drug pricing (3)
Duchenne muscular dystrophy (40)
Earnings (15787)
Editorial (2)
Events (5402)
Executive appointments (25)
FDA (1005)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (5)
Funding (41)
Gene editing (9)
Generative AI (2)
Gene therapy (35)
GLP-1 (49)
Government (131)
Guidances (167)
Healthcare (1068)
HIV (3)
Huntington's disease (2)
IgA nephropathy (10)
Immunology and inflammation (18)
Immuno-oncology (4)
Indications (8)
Infectious disease (92)
Inflammatory bowel disease (11)
Influenza (2)
Intellectual property (10)
Interviews (2)
IPO (2254)
Job creations (71)
Job search strategy (13)
JPM (3)
Labor market (2)
Layoffs (24)
Leadership (2)
Legal (230)
Liver cancer (3)
Longevity (1)
Lung cancer (34)
Lymphoma (66)
Machine learning (2)
Manufacturing (10)
MASH (10)
Medical device (939)
Medtech (943)
Mergers & acquisitions (644)
Metabolic disorders (91)
Multiple sclerosis (11)
NASH (2)
Neurodegenerative disease (18)
Neuropsychiatric disorders (11)
Neuroscience (144)
NextGen: Class of 2026 (218)
Non-profit (69)
Now hiring (1)
Obesity (31)
Opinion (12)
Ovarian cancer (8)
Pain (17)
Pancreatic cancer (13)
Parkinson's disease (14)
Partnered (3)
Patents (28)
Patient recruitment (18)
Peanut (3)
People (1292)
Pharmaceutical (3)
Pharmacy benefit managers (1)
Phase 1 (1347)
Phase 2 (2085)
Phase 3 (1768)
Pipeline (866)
Policy (7)
Postmarket research (171)
Preclinical (431)
Prostate cancer (15)
Psychedelics (1)
Radiopharmaceuticals (11)
Rare diseases (55)
Real estate (160)
Regulatory (1214)
Reports (3)
Research institute (59)
Resumes & cover letters (4)
Rett syndrome (9)
RNA editing (2)
RSV (6)
Schizophrenia (15)
Series A (4)
Series B (2)
Service/supplier (1)
Sickle cell disease (1)
Spinal muscular atrophy (1)
Sponsored (2)
Startups (131)
Stomach cancer (3)
Supply chain (3)
Tariffs (2)
Vaccines (41)
Venture capital (1)
Weight loss (25)
Women's health (6)
Date
Last 7 days (42)
Last 30 days (130)
Last 365 days (2905)
2026 (150)
2025 (2975)
2024 (2964)
2023 (3386)
2022 (3623)
2021 (3851)
2020 (3178)
2019 (2152)
2018 (1564)
2017 (1440)
2016 (1038)
2015 (1528)
2014 (994)
2013 (525)
2012 (613)
2011 (867)
2010 (732)
Location
Africa (19)
Alabama (6)
Arizona (25)
Asia (2798)
Australia (229)
California (1006)
Canada (204)
China (68)
Colorado (46)
Connecticut (86)
Delaware (49)
Europe (4802)
Florida (121)
Georgia (28)
Illinois (68)
India (4)
Indiana (60)
Iowa (9)
Japan (41)
Kansas (6)
Kentucky (3)
Louisiana (6)
Maine (6)
Maryland (79)
Massachusetts (585)
Michigan (20)
Minnesota (62)
Missouri (11)
Montana (2)
Nevada (5)
New Hampshire (8)
New Jersey (475)
New York (252)
North Carolina (116)
Northern California (556)
Ohio (27)
Oklahoma (1)
Oregon (1)
Pennsylvania (211)
Puerto Rico (3)
South America (35)
South Carolina (1)
Southern California (355)
Tennessee (4)
Texas (173)
United States (3725)
Utah (42)
Virginia (41)
Washington D.C. (4)
Washington State (178)
Wisconsin (3)
41,907 Results for "102".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program
January 27, 2026
·
7 min read
Press Releases
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome
January 6, 2026
·
7 min read
Press Releases
Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors
January 27, 2026
·
9 min read
Press Releases
Abpro’s Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference
January 16, 2026
·
5 min read
Press Releases
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
January 8, 2026
·
6 min read
Press Releases
Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72
January 6, 2026
·
8 min read
Press Releases
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
December 5, 2025
·
8 min read
Press Releases
EnteroBiotix announces positive Phase 2 TrIuMPH results supporting EBX-102-02 as a potential first-in-class, oral, full-spectrum microbiome therapy for irritable bowel syndrome
January 8, 2026
·
5 min read
Press Releases
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
January 21, 2026
·
8 min read
Press Releases
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
January 13, 2026
·
9 min read
1 of 4,191
Next
